Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2013 Mar-Apr;20(2):117-20.
doi: 10.1155/2013/602936.

Update on clinical inflammometry for the management of airway diseases

Parameswaran Nair  1
Affiliations
Review

Update on clinical inflammometry for the management of airway diseases

Parameswaran Nair. Can Respir J. 2013 Mar-Apr.

Abstract
in English, French

Airway inflammation is a central feature of many airway diseases such as asthma, chronic bronchitis, bronchiectasis and chronic cough; therefore, it is only logical that it is measured to optimize its treatment. However, most treatment recommendations, including the use of anti-inflammatory therapies such as corticosteroids, are based on assessments of only airflow and symptoms. Over the past 10 years, methods have been developed to assess airway inflammation relatively noninvasively. Quantitative cell counts in sputum and the fraction of exhaled nitric oxide are the most validated tests. Judicious use of currently available drugs, such as corticosteroids, bronchodilators and antibiotics, and other anti-inflammatory therapies guided by sputum eosinophil and neutrophil counts, have been demonstrated to decrease exacerbations of asthma and chronic obstructive pulmonary disease, ameliorate cough, improve quality of life in patients with these diseases and is cost effective compared with treatment strategies based on guidelines that do not incorporate these measurements. Thus, it is unfortunate that this is not used more widely in the management of airway diseases, particularly in patients with severe asthma and chronic obstructive pulmonary disease who experience frequent exacerbations.

L’inflammation des voies respiratoires est un élément central de nom-breuses maladies des voies respiratoires comme l’asthme, la bronchite chronique, la bronchiectasie et la toux chronique. Par conséquent, il est logique de la mesurer pour en optimiser le traitement. Cependant, la plu-part des recommandations thérapeutiques, y compris le recours à des traite-ments anti-inflammatoires comme les corticoïdes, se fondent sur des évaluations limitées au débit respiratoire et aux symptômes. Depuis dix ans, des méthodes ont été mises au point pour évaluer l’inflammation des voies respiratoires de manière relativement non envahissante. Le dénombrement cellulaire quantitatif dans les expectorations et la fraction de monoxyde d’azote exhalé sont les tests les plus validés. Il est démontré qu’une utilisation judicieuse des médicaments sur le marché, tels que les corticoïdes, les bronchodilatateurs et les antibiotiques, et d’autres traitements anti-inflammatoires sélectionnés selon la numération des éosinophiles et des neutrophiles dans les expectorations, réduit les exacerbations d’asthme et de maladie pulmonaire obstructive chronique, limite la toux, améliore la qualité de vie chez les patients atteints de ces maladies et est rentable par rapport à des stratégies thérapeutiques fondées sur des lignes directrices qui n’intègrent pas ces mesures. Il est donc malheureux qu’on ne l’utilise pas de manière plus généralisée pour traiter les maladies des voies respiratoires, notamment chez les patients atteints d’asthme grave et de maladie pulmo-naire obstructive chronique qui présentent de fréquentes exacerbations.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

  • Guidelines for diagnosis and management of bronchial asthma: Joint ICS/NCCP (I) recommendations.
    Agarwal R, Dhooria S, Aggarwal AN, Maturu VN, Sehgal IS, Muthu V, Prasad KT, Yenge LB, Singh N, Behera D, Jindal SK, Gupta D, Balamugesh T, Bhalla A, Chaudhry D, Chhabra SK, Chokhani R, Chopra V, Dadhwal DS, D'Souza G, Garg M, Gaur SN, Gopal B, Ghoshal AG, Guleria R, Gupta KB, Haldar I, Jain S, Jain NK, Jain VK, Janmeja AK, Kant S, Kashyap S, Khilnani GC, Kishan J, Kumar R, Koul PA, Mahashur A, Mandal AK, Malhotra S, Mohammed S, Mohapatra PR, Patel D, Prasad R, Ray P, Samaria JK, Singh PS, Sawhney H, Shafiq N, Sharma N, Sidhu UP, Singla R, Suri JC, Talwar D, Varma S. Agarwal R, et al. Lung India. 2015 Apr;32(Suppl 1):S3-S42. doi: 10.4103/0970-2113.154517. Lung India. 2015. PMID: 25948889 Free PMC article. No abstract available.
  • Distinguishing adult-onset asthma from COPD: a review and a new approach.
    Abramson MJ, Perret JL, Dharmage SC, McDonald VM, McDonald CF. Abramson MJ, et al. Int J Chron Obstruct Pulmon Dis. 2014 Sep 9;9:945-62. doi: 10.2147/COPD.S46761. eCollection 2014. Int J Chron Obstruct Pulmon Dis. 2014. PMID: 25246782 Free PMC article. Review.
  • Therapeutic potential of anti-IL-6 therapies for granulocytic airway inflammation in asthma.
    Chu DK, Al-Garawi A, Llop-Guevara A, Pillai RA, Radford K, Shen P, Walker TD, Goncharova S, Calhoun WJ, Nair P, Jordana M. Chu DK, et al. Allergy Asthma Clin Immunol. 2015 Apr 12;11(1):14. doi: 10.1186/s13223-015-0081-1. eCollection 2015. Allergy Asthma Clin Immunol. 2015. PMID: 25878673 Free PMC article.
  • Evidence of eosinophil extracellular trap cell death in COPD: does it represent the trigger that switches on the disease?
    Uribe Echevarría L, Leimgruber C, García González J, Nevado A, Álvarez R, García LN, Quintar AA, Maldonado CA. Uribe Echevarría L, et al. Int J Chron Obstruct Pulmon Dis. 2017 Mar 14;12:885-896. doi: 10.2147/COPD.S115969. eCollection 2017. Int J Chron Obstruct Pulmon Dis. 2017. PMID: 28352169 Free PMC article.

References

    1. Djukanovic R, Roche WR, Wilson JW, et al. Mucosal inflammation in asthma. Am Rev Respir Dis. 1990;142:434–57. - PubMed
    1. Nair P, Pizzichini E, Pizzichini MM, Hussack P, Efthimiadis A, Hargreave FE. Clinical judgement of airway inflammation versus sputum cell counts in patients with asthma. Eur Respir J. 2000;15:486–90. - PubMed
    1. O’Donnell DE, Aaron S, Bourbeau J, et al. Canadian Thoracic Society recommendations for management of chronic obstructive pulmonary disease – 2007 update. Can Respir J. 2007;14(Suppl B):5B–32B. - PMC - PubMed
    1. Lougheed MD, Lemiere C, Ducharme FM, et al. Canadian Thoracic Society 2012 guideline update: Diagnosis and management of asthma in preschoolers, children and adults. Can Respir J. 2012;19:127–64. - PMC - PubMed
    1. Popov TA, Pizzichini MM, Pizzichini E, et al. Some technical factors influencing the induction of sputum for cell analysis. Eur Respir J. 1995;8:559–65. - PubMed

MeSH terms